Explore
Upload

DocSlides is a free service to upload presentations and documents.

Upload Now

Search Results for 'Heparin Rivaroxaban'

Heparin Rivaroxaban published presentations and documents on DocSlides.

Thromboembolic protocols

Thromboembolic protocols

  • cecilia
  • 27 Slides

& safe anticoagulant prescribing. July 2020. D...

Rivaroxaban compared with enoxaparin for the prevention of

Rivaroxaban compared with enoxaparin for the prevention of

  • luanne-stotts
  • 21 Slides

Alexander T Cohen . On behalf of the MAGELLAN Ste...

Rivaroxaban or Aspirin for Extended Treatment of Venous Thr

Rivaroxaban or Aspirin for Extended Treatment of Venous Thr

  • yoshiko-marsland
  • 25 Slides

(EINSTEIN CHOICE). Ryan Sparks, . PharmD. , BCPS....

A Multicenter Randomized Trial Evaluating Clinically Significant Bleeding with Low-Dose Rivaroxaban

A Multicenter Randomized Trial Evaluating Clinically Significant Bleeding with Low-Dose Rivaroxaban

  • celsa-spraggs
  • 0 Slides

Magnus Ohman MB, on behalf of the GEMINI-ACS-1 In...

Rivaroxaban Plus Aspirin in Patients With and Without Heart Failure and Chronic Coronary or Peripheral Artery Disease:

Rivaroxaban Plus Aspirin in Patients With and Without Heart Failure and Chronic Coronary or Peripheral Artery Disease:

  • giovanna-bartolotta
  • 15 Slides

Rivaroxaban Plus Aspirin in Patients With and Wit...

HEPARIN INDUCED THROMBOCYTOPENIA

HEPARIN INDUCED THROMBOCYTOPENIA

  • ellena-manuel
  • 50 Slides

(HIT). HEPARIN-INDUCED THROMBOCYTOPENIA. Unfracti...

Efficacy and Safety of Low Molecular Weight Heparin compared to Unfractionated Heparin for Chronic

Efficacy and Safety of Low Molecular Weight Heparin compared to Unfractionated Heparin for Chronic

  • mitsue-stanley
  • 0 Slides

R. eview and Meta-Analysis.. Dinesh Keerty, MD. T...

Bivalirudin Plus a High-dose Infusion Versus Heparin Monotherapy in Patients with STEMI Undergoing

Bivalirudin Plus a High-dose Infusion Versus Heparin Monotherapy in Patients with STEMI Undergoing

  • roberts
  • 20 Slides

The BRIGHT-4 Trial. Gregg W. Stone MD. On behalf o...

Recent ACS: STEMI, NSTEMI, UA

Recent ACS: STEMI, NSTEMI, UA

  • danika-pritchard
  • 20 Slides

Stabilized 1-7 Days Post-Index Event. Exclusions:...

A New Era in Anticoagulation Management

A New Era in Anticoagulation Management

  • debby-jeon
  • 46 Slides

Allyson Sarigianis, Pharm.D.. October 19, 2013. O...

Novel Oral Anticoagulants

Novel Oral Anticoagulants

  • natalia-silvester
  • 88 Slides

(. N. OAC). Dan . Moellentin. , . PharmD. , BCPS,...

A Multicenter Randomized Trial Evaluating Clinically Signif

A Multicenter Randomized Trial Evaluating Clinically Signif

  • ellena-manuel
  • 20 Slides

Magnus Ohman MB, on behalf of the GEMINI-ACS-1 In...

R eal-world

R eal-world

  • liane-varnes
  • 20 Slides

EVI. dence. on . S. troke prevention . I. n pati...

New Oral Anticoagulant

New Oral Anticoagulant

  • mitsue-stanley
  • 80 Slides

R2 Patcharee Seesongsom. R2 . Sirada. . Phoja...

A Multicenter Randomized Trial Evaluating Clinically Signif

A Multicenter Randomized Trial Evaluating Clinically Signif

  • giovanna-bartolotta
  • 20 Slides

Magnus Ohman MB, on behalf of the GEMINI-ACS-1 In...

Stroke, Bleeding, and

Stroke, Bleeding, and

  • lois-ondreau
  • 7 Slides

Mortality Risks . in . Elderly Medicare Beneficia...

A New Era in Anticoagulation Management

A New Era in Anticoagulation Management

  • alexa-scheidler
  • 0 Slides

Allyson Sarigianis, Pharm.D.. October 19, 2013. O...

CAD/PAD in Primary Care CV Risk in Stable Outpatients

CAD/PAD in Primary Care CV Risk in Stable Outpatients

  • stefany-barnette
  • 0 Slides

Stratified by Baseline CV Risk Category. Aspirin ...

Dr. Phil Wells on behalf of the EINSTEIN CHOICE Steering Committee and Investigators

Dr. Phil Wells on behalf of the EINSTEIN CHOICE Steering Committee and Investigators

  • yoshiko-marsland
  • 18 Slides

Dr. Phil Wells on behalf of the EINSTEIN CHOICE ...

A ssessment of D ual antiplatelet therapy versus

A ssessment of D ual antiplatelet therapy versus

  • stefany-barnette
  • 22 Slides

A ssessment of D ual antiplatelet therapy versus...

Ima A. Kusuma , MD, FIHA

Ima A. Kusuma , MD, FIHA

  • hirook
  • 33 Slides

“JIH. ” Hospital, Yogyakarta, Indonesia. The U...

A ssessment of D ual antiplatelet therapy versus

A ssessment of D ual antiplatelet therapy versus

  • coursion
  • 22 Slides

R. ivaroxaban . I. n atrial . F. ibrillation patie...

Rivaroxaban in stable peripheral or carotid artery disease

Rivaroxaban in stable peripheral or carotid artery disease

  • basidell
  • 17 Slides

Sonia Anand, on . behalf of the COMPASS Steering C...

X- VeRT CV death, stroke/TIA, non-CNS systemic embolism, or MI: 0.51% of the

X- VeRT CV death, stroke/TIA, non-CNS systemic embolism, or MI: 0.51% of the

  • LittleMissPerfect
  • 1 Slides

rivaroxaban. group vs. 1.02% of the vitamin K ant...

MAGELLAN Primary efficacy endpoint at 10 days (DVT, symptomatic PE,

MAGELLAN Primary efficacy endpoint at 10 days (DVT, symptomatic PE,

  • HoneyBun
  • 1 Slides

VTE death. ) for . rivaroxaban. vs. . enoxaparin....

Review on NOACs Studies Dr.

Review on NOACs Studies Dr.

  • BlessedBeyondMeasure
  • 37 Slides

Kourosh. . Sadeghi. Tehran University of medical ...

Reversing Course: Managing Anticoagulation and Antiplatelet Bleeding

Reversing Course: Managing Anticoagulation and Antiplatelet Bleeding

  • kyle585
  • 20 Slides

Paul P. . Dobesh. , . Pharm.D. , FCCP, BCPS, BCCP....

Heparin Induced Thrombocytopenia There are t wo forms of thrombocytopenia that can occur from heparin exposure non immune and immune mediated

Heparin Induced Thrombocytopenia There are t wo forms of thrombocytopenia that can occur from heparin exposure non immune and immune mediated

  • conchita-marotz
  • 3 Slides

The immune mediated form can lead to thrombo sis ...

Anticoagulation Reversal

Anticoagulation Reversal

  • test
  • 102 Slides

May 11, 2013. Objectives. Develop an approach for...

Advanced Calculations

Advanced Calculations

  • luanne-stotts
  • 26 Slides

Nursing 201. Ms. Frasier. Summer 2014. Dimensiona...

Blood Pharmacology

Blood Pharmacology

  • faustina-dinatale
  • 12 Slides

Peer Support 2014. Case 1. Mrs. A recently seen ...

Chapter 52

Chapter 52

  • conchita-marotz
  • 34 Slides

Anticoagulant, Antiplatelet, and Thrombolytic Dru...

ANTICOAGULANT BY :DR ISRAA OMAR

ANTICOAGULANT BY :DR ISRAA OMAR

  • faustina-dinatale
  • 0 Slides

Definition of Anticoagulation. Therapeutic interf...

Anticoagulation on dialysis

Anticoagulation on dialysis

  • alexa-scheidler
  • 0 Slides

. . Feb 08/2014. Hanadi. . Alhozali,MBBS,ABIM,...

Anticoagulation on dialysis

Anticoagulation on dialysis

  • alida-meadow
  • 0 Slides

. . Feb 08/2014. Hanadi. . Alhozali,MBBS,ABIM,...

Thrombocytopenia Block 14, 2014-2015

Thrombocytopenia Block 14, 2014-2015

  • liane-varnes
  • 0 Slides

Articles. by . Ryan Burris, Ali Naqvi, Wendy Yan...

Fallacies of Coagulation Testing

Fallacies of Coagulation Testing

  • mitsue-stanley
  • 0 Slides

Ravi Sarode, MD. John H Childers Professorship in...

Argatroban as an Alternative to Heparin for Vascular and Cardiovascular Surgery in Patients with a History of HIT

Argatroban as an Alternative to Heparin for Vascular and Cardiovascular Surgery in Patients with a History of HIT

  • giovanna-bartolotta
  • 33 Slides

Argatroban as an Alternative to Heparin for Vascu...

Bivalirudin in 2015- An update with the MATRIX study

Bivalirudin in 2015- An update with the MATRIX study

  • kaptainpositive
  • 38 Slides

Bernardo Cortese. Intv. ’ . Cardiology. , A.O. F...

La bivalirudina ed il

La bivalirudina ed il

  • alone2cute
  • 35 Slides

. suo. . annus. . horribilis. : un update . scie...

Copyright © 2024 DocSlides. All Rights Reserved